UPClytics
Overview · Filed: May 13, 2024

UPC_CFI_146/2024

NOVEL ANTITUMORAL USE OF CABAZITAXEL

InfringementMain Infringement ActionMunich LDInfringementCase Closed
  • 2025-12-12Procedural onlyproceduralInfringement Action

    The Munich Local Division issued a rectification order under Rule 353 RoP correcting factual errors in a prior decision in the Sanofi v. Stada/Dr Reddy/Zentiva proceedings, including corrections regarding marketing authorisation holders and expert witness attribution.

  • 2025-12-12Revokedinfringement_meritsInfringement Action

    The Munich Local Division found patent EP 2 493 466 (relating to cabazitaxel pharmaceutical formulations) invalid for lack of inventive step in infringement proceedings brought by Sanofi against STADA, Dr. Reddy's and Zentiva entities, dismissing the infringement claims.